Boston's Liberte bare-metal stent:
This article was originally published in Clinica
Boston Scientific has received Japanese approval for its bare-metal stent, Liberte, which also serves as the platform for the firm's second-generation paclitaxel-eluting stent, Taxus Liberte. "The approval of our Liberte stent represents an important step in the evolution of our drug-eluting stent (DES) programme in Japan," said Paul LaViolette, Boston's COO. The firm's Taxus Liberte has been CE-marked for sale in Europe since September 2005, and it hopes to launch the DES in the US during 2007. The firm is not yet ready to speculate on when the DES is likely to penetrate the Japanese market, but claims that it can now look forward to long-awaited Japanese approval of its first-generation Taxus Express 2 stent in mid-2007. Boston claims that Liberte provides physicians with enhanced lesion access in challenging anatomy due to its thin struts and highly flexible cell design.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.